All In Biotech

Drug Trial Radar · NCT02017613

Safety and Efficacy Study of a Dual PI3K Delta/Gamma Inhibitor in Hematological Malignancies

A Phase I, Dose Escalation Study to Evaluate Safety and Efficacy of RP6530, a Dual PI3K Delta/Gamma Inhibitor, in Patients With Relapsed or Refractory Hematologic Malignancies

Last checked: Nov 19, 2026Latest source record: Jun 24, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

35

Actual

Start

Nov 2013

Primary completion

May 2016

Study completion May 2016

Sponsor

Lead sponsor
Rhizen Pharmaceuticals SAIndustry
Sponsor type
Industry
First posted
Dec 23, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The objective of this study is to evaluate the safety and efficacy of RP6530, a dual PI3K delta/gamma inhibitor in patients with hematologic malignancies.

Conditions

  • Lymphoma, B-Cell
  • T-Cell Lymphoma

Interventions

  • RP6530Drug

    Escalating doses starting at 25 mg BID

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum tolerated dose (MTD) and pharmacokinetics (PK) of RP6530Time frame: 28 days

Locations

3 sites in 2 countries. Site status is shown where the registry gives one.

  • Rhizen Trial Site

    Paris, France

  • Rhizen Trial Site 1

    Milan, Italy

  • Rhizen Trial Site 2

    Milan, Italy

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.